Hypofractionated Radiochemotherapy

The goal of this clinical trial is to investigate the use of hypofractionated radiation (delivery of fewer but larger doses of radiation) with concurrent chemotherapy for women with metastatic of bulky uterine cervix cancer. The main questions it aims to answer are: * What is the MRI-assessed rate of response at 1-month and 3-months post-treatment? * What is the safety and tolerability of cisplatin-based hypofractionated pelvic Intensity Modulated Radiation Therapy (IMRT) followed by brachytherapy? * What is the median progression-free survival and overall survival at 1 and 2 years for patien

Trial Details

NCT ID
NCT06331468
Phase
PHASE2
Sponsor
Denise Fabian
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Cisplatin
  • intensity modulated radiation therapy (IMRT)
  • high-dose-rate (HDR) brachytherapy
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

  • Untreated, pathologically or cytologically-confirmed diagnosis of FIGO Stage IB3, II, or IIIA-IIIC1 bulky ( ≥ 6cm) or Stage IVA or Stage IVB (FIGO …
  • Adequate organ and marrow function
  • Gynecologic Oncology Group performance status of 0, 1, or 2
  • Patient agrees to use two forms of birth control if they are of child-bearing potential

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →